There is disclosed compositions and methods relating to or derived from anti-JAG1 antibodies. More specifically, there is disclosed fully human antibodies that bind JAG1, JAG1-binding fragments and derivatives of such antibodies, and JAG1 -binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having JAG1 related disorders or conditions. There is also disclosed a method for treating JAG1-expressing tumors, including hepatocellular carcinomas and squamous carcinomas, and non-oncology diseases selected from the group consisting of rheumatoid arthritis, experimental lung injury, atherosclerosis, chronic liver disease induced by hepatitis C virus, ischemic myocardial injury and heart failure.本發明揭示抗JAG1抗體相關或衍生之組合物及方法。更特定地，本發明揭示結合JAG1之完全人類抗體、該等抗體之JAG1結合片段及衍生物，及包含該等片段之JAG1結合多肽。另外，本發明揭示編碼該等抗體、抗體片段及衍生物及多肽之核酸；包含該等聚核苷酸之細胞；製備該等抗體、抗體片段及衍生物及多肽之方法；及使用該等抗體、抗體片段及衍生物及多肽之方法，包括治療或診斷具有JAG1相關病症或病狀之個體之方法。亦揭示一種用於治療JAG1表現腫瘤(包括肝細胞癌及鱗狀癌)及非腫瘤疾病(選自由以下組成之群：類風濕性關節炎、實驗性肺損傷、動脈粥樣硬化、C型肝炎病毒誘發之慢性肝病、缺血性心肌損傷及心臟衰竭)之方法。
